Abstract:IL-12 is an immune-stimulatory cytokine that can modulate the tumor microenvironmnent (TME) to enhance the cytotoxic activity of T and NK cells; however, IL-12 expression by T cells caused severe toxicity in a previous clinical trial. Using Outpace's OutSmartTM technology, we designed a tumor-restricted IL-12 (trIL-12) that is under control of an activation-inducible promoter and auto-inactivates within minutes after secretion. T cells were engineered via lentiviral vectors (LVV) to express wild-type single-chain IL-12 (WT scIL-12) or trIL-12 under the control of an activation-inducible promoter; a second LVV introduces an NY-ESO-1 TCR. Kinetics of IL-12 expression was measured by qPCR and MSD technology; kinetics of IL-12p70 heterodimer half-life was measured using Octet bio-layer interferometry (BLI). T-cell cytotoxicity and cytokine production was evaluated in vitro after repeated stimulation with NY-ESO-1 expressing target cells using Incucyte and MSD. IL-12 activity in bystander cells was measured by detection of IFN-γ using flow cytometry. In vivo T-cell function of trIL-12-engineered NY-ESO-1 TCR T cells was measured in NSG MHCI/II KO mice bearing A375 xenografts. trIL-12 activity in a fully immune-competent mouse model was measured in B6 mice implanted with B16F10 tumor cells engineered to express murine surrogates of trIL-12. Expression of WT scIL-12 under the control of an activation-inducible promoter peaks within 6 hours after activation and produces sufficient IL-12 to improve T-cell function in vitro and in vivo. trIL-12 was created by inclusion of a cleavable linker and elimination of the covalent disulfide bond between the p35 and p40 subunits of IL-12p70, resulting in dissociation of the functional cytokine within 10 minutes post-cleavage. Additional mutations further reduce the IL-12p70 half-life. trIL-12 activates the IL-12-producing T cells, as well as proximal bystander T-cells in direct co-culture, but it does not have the ability to activate distal bystander T-cells separated by Transwell membranes. In xenograft mouse models, trIL-12-expressing T cells have improved proliferation upon antigen recognition and display potent anti-tumor activity and cytokine production without showing systemic IL-12 accumulation. Furthermore, in fully immune competent mice, expression of a murine trIL-12 surrogate by tumor cells led to generation of potent anti-tumor responses without systemic trIL-12 accumulation and reduced systemic IFN-γ. trIL-12-engineered T cells generate potent anti-tumor activity in vitro and in vivo. Unlike WT scIL-12, trIL-12 activity is localized to the region around the producing T cell and systemic IL-12 exposure is not observed in vivo. Collectively, these preclinical data suggest that trIL-12 may enable the development of potent T-cell therapeutics while maintaining an acceptable safety profile. Citation Format: Szu-Han Huang, Thaddeus M. Davenport, Howell F. Moffett, Brian D. Weitzner, Luke Cassereau, Laura E. Baker, Bradley Hammerson, Summer Zhuang, Christine Saechao, Lisa Song, Jade Mimms, David Chian, Candace Sims, Hajime Hiraragi, Marc J. Lajoie, Scott E. Boyken, Bijan Boldajipour. Development of tumor-restricted IL-12 with antigen-dependent expression and localized IL-12 activity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 4067.

CRS Free T Cell Therapy: T Cell Membrane Anchored and Tumor Targeted IL12 (ATTIL12)-T Cell Therapy Eliminates Large Tumors, Overcomes Heterogeneity, and Avoids Adverse Effects

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.

Abstract 5568: Revitalization of affinity-tuned CAR T cells via antigen-dependent release of interleukin-12

Abstract 558: Focused IL-12 cytokine delivery enhances function of affinity-tuned and real-time tracked ICAM-1-specific CAR T cells in solid tumors

Membrane-Anchored and Tumor-Targeted IL12 (attIL12)-PBMC Therapy for Osteosarcoma

rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors

Abstract LB344: A novel approach to limit off-tumor toxicity of CAR-T cells targeting solid cancers

Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects

Abstract 4087: Co-expression of membrane bound IL-15 enhanced anti-tumor response of CAR-T

IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin

TCR-T Immunotherapy: The Challenges and Solutions

PD-1-CD28-enhanced receptor and CD19 CAR-modified tumor-infiltrating T lymphocytes produce potential anti-tumor ability in solid tumors

Progress of IL-12 in Tumor Immunotherapy

Abstract LB067: Tumor-reactive CD8 TIL with an exhausted phenotype can be expanded and regress human tumors

Treatment of aggressive T-cell lymphoma/leukemia with anti-CD4 CAR T cells

Abstract 4067: Development of tumor-restricted IL-12 with antigen-dependent expression and localized IL-12 activity

Abstract 6322: CCTx-001 CAR T-cells targeting the AML specific antigen IL-1RAP show robust pre-clinical anti-tumor efficacy

Abstract B050: A novel approach and model to limit cytokine release syndrome and off-tumor toxicity of synthetically enhanced CEA CAR-T cells

IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models

Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86–Positive B Cell Malignancies

TRLS-05. PRELIMINARY RESULTS FROM A PHASE I TRIAL TO EVALUATE INTRAVENTRICULAR DELIVERY OF IL13RΑ2-TARGETING CAR T CELLS AFTER LYMPHODEPLETION IN PEDIATRIC BRAIN TUMORS PATIENTS